{"id":"https://openalex.org/W3012537592","doi":"https://doi.org/10.1002/prp2.567","title":"Population pharmacokinetic and exposure\u2010response analysis of eptinezumab in the treatment of episodic and chronic migraine","display_name":"Population pharmacokinetic and exposure\u2010response analysis of eptinezumab in the treatment of episodic and chronic migraine","publication_year":2020,"publication_date":"2020-03-10","ids":{"openalex":"https://openalex.org/W3012537592","doi":"https://doi.org/10.1002/prp2.567","mag":"3012537592","pmid":"https://pubmed.ncbi.nlm.nih.gov/32155317","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/7064329"},"language":"en","primary_location":{"id":"doi:10.1002/prp2.567","doi":"https://doi.org/10.1002/prp2.567","is_oa":true,"landing_page_url":"https://doi.org/10.1002/prp2.567","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/prp2.567","source":{"id":"https://openalex.org/S2764487716","display_name":"Pharmacology Research & Perspectives","issn_l":"2052-1707","issn":["2052-1707"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmacology Research & Perspectives","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/prp2.567","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"Brian Baker","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210150391","display_name":"Lundbeck (United States)","ror":"https://ror.org/04a2yjk98","country_code":"US","type":"company","lineage":["https://openalex.org/I133593841","https://openalex.org/I4210150391"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Brian Baker","raw_affiliation_strings":["Lundbeck Seattle BioPharmaceuticals, Bothell, WA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lundbeck Seattle BioPharmaceuticals, Bothell, WA, USA","institution_ids":["https://openalex.org/I4210150391"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112009508","display_name":"Barbara A. Schaeffler","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210150391","display_name":"Lundbeck (United States)","ror":"https://ror.org/04a2yjk98","country_code":"US","type":"company","lineage":["https://openalex.org/I133593841","https://openalex.org/I4210150391"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Barbara Schaeffler","raw_affiliation_strings":["Lundbeck Seattle BioPharmaceuticals, Bothell, WA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lundbeck Seattle BioPharmaceuticals, Bothell, WA, USA","institution_ids":["https://openalex.org/I4210150391"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045428639","display_name":"Martin B\u00e9liveau","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Martin Beliveau","raw_affiliation_strings":["Certara Strategic Consulting, Montreal, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Certara Strategic Consulting, Montreal, Canada","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060329122","display_name":"Igor Rubets","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Igor Rubets","raw_affiliation_strings":["Certara Strategic Consulting, Montreal, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Certara Strategic Consulting, Montreal, Canada","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103450536","display_name":"Susan M. Pederson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210150391","display_name":"Lundbeck (United States)","ror":"https://ror.org/04a2yjk98","country_code":"US","type":"company","lineage":["https://openalex.org/I133593841","https://openalex.org/I4210150391"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Susan Pederson","raw_affiliation_strings":["Lundbeck Seattle BioPharmaceuticals, Bothell, WA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lundbeck Seattle BioPharmaceuticals, Bothell, WA, USA","institution_ids":["https://openalex.org/I4210150391"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110709605","display_name":"My My Trinh","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"MyMy Trinh","raw_affiliation_strings":["Certara Strategic Consulting, Montreal, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Certara Strategic Consulting, Montreal, Canada","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039406215","display_name":"Jeff Smith","orcid":"https://orcid.org/0000-0002-3265-7184","observed_orcids":["https://orcid.org/0000-0002-3265-7184"]},"institutions":[{"id":"https://openalex.org/I4210150391","display_name":"Lundbeck (United States)","ror":"https://ror.org/04a2yjk98","country_code":"US","type":"company","lineage":["https://openalex.org/I133593841","https://openalex.org/I4210150391"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jeff Smith","raw_affiliation_strings":["Lundbeck Seattle BioPharmaceuticals, Bothell, WA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lundbeck Seattle BioPharmaceuticals, Bothell, WA, USA","institution_ids":["https://openalex.org/I4210150391"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5081580924","display_name":"John A Latham","orcid":"https://orcid.org/0000-0002-3034-1768","observed_orcids":["https://orcid.org/0000-0002-3034-1768"]},"institutions":[{"id":"https://openalex.org/I4210150391","display_name":"Lundbeck (United States)","ror":"https://ror.org/04a2yjk98","country_code":"US","type":"company","lineage":["https://openalex.org/I133593841","https://openalex.org/I4210150391"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John Latham","raw_affiliation_strings":["Lundbeck Seattle BioPharmaceuticals, Bothell, WA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lundbeck Seattle BioPharmaceuticals, Bothell, WA, USA","institution_ids":["https://openalex.org/I4210150391"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210150391"],"apc_list":{"value":2500,"currency":"USD","value_usd":2500},"apc_paid":{"value":2500,"currency":"USD","value_usd":2500},"fwci":5.0811,"has_fulltext":true,"cited_by_count":66,"citation_normalized_percentile":{"value":0.97010943,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":98,"max":99},"biblio":{"volume":"8","issue":"2","first_page":"e00567","last_page":"e00567"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10498","display_name":"Migraine and Headache Studies","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10498","display_name":"Migraine and Headache Studies","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12547","display_name":"Pharmaceutical studies and practices","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12255","display_name":"Biosimilars and Bioanalytical Methods","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/eptinezumab","display_name":"eptinezumab","score":1.0},{"id":"https://openalex.org/keywords/migraine-prevention","display_name":"migraine prophylaxis","score":0.6209999918937683},{"id":"https://openalex.org/keywords/episodic-migraine","display_name":"episodic migraine","score":0.9890000224113464},{"id":"https://openalex.org/keywords/chronic-migraine","display_name":"chronic migraine","score":1.0},{"id":"https://openalex.org/keywords/calcitonin-gene-related-peptide","display_name":"calcitonin gene-related peptide","score":0.9319999814033508},{"id":"https://openalex.org/keywords/monoclonal-antibodies","display_name":"monoclonal antibodies","score":0.8600000143051147},{"id":"https://openalex.org/keywords/population-pharmacokinetics","display_name":"population pharmacokinetics","score":0.9750000238418579},{"id":"https://openalex.org/keywords/exposure-response-relationship","display_name":"exposure-response relationship","score":0.8119999766349792},{"id":"https://openalex.org/keywords/dose-response-relationship","display_name":"dose-response relationship","score":0.7609999775886536},{"id":"https://openalex.org/keywords/ec90","display_name":"EC90","score":0.7670000195503235},{"id":"https://openalex.org/keywords/dosing-interval","display_name":"dosing interval","score":0.5569999814033508},{"id":"https://openalex.org/keywords/intravenous-administration","display_name":"intravenous administration","score":0.6430000066757202},{"id":"https://openalex.org/keywords/monthly-migraine-days","display_name":"monthly migraine days","score":0.4869999885559082}],"concepts":[{"id":"https://openalex.org/C2778541695","wikidata":"https://www.wikidata.org/wiki/Q133823","display_name":"Migraine","level":2,"score":0.697637677192688},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6455402970314026},{"id":"https://openalex.org/C2910587157","wikidata":"https://www.wikidata.org/wiki/Q133823","display_name":"Chronic Migraine","level":3,"score":0.5609830021858215},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.4680449962615967},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.33855360746383667},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.07806897163391113}],"mesh":[{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002908","descriptor_name":"Chronic Disease","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008881","descriptor_name":"Migraine Disorders","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D008881","descriptor_name":"Migraine Disorders","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D008954","descriptor_name":"Models, Biological","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D015740","descriptor_name":"Calcitonin Gene-Related Peptide","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true}],"locations_count":5,"locations":[{"id":"doi:10.1002/prp2.567","doi":"https://doi.org/10.1002/prp2.567","is_oa":true,"landing_page_url":"https://doi.org/10.1002/prp2.567","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/prp2.567","source":{"id":"https://openalex.org/S2764487716","display_name":"Pharmacology Research & Perspectives","issn_l":"2052-1707","issn":["2052-1707"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmacology Research & Perspectives","raw_type":"journal-article"},{"id":"pmh:oai:europepmc.org:6026089","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/7064329","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":null,"raw_type":"Text"},{"id":"pmh:oai:pubmedcentral.nih.gov:7064329","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/7064329","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmacol Res Perspect","raw_type":"Text"},{"id":"pmid:32155317","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/32155317","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmacology research & perspectives","raw_type":"Journal Article"},{"id":"pmh:oai:doaj.org/article:a56afb6aaef44d81bc49cf66a20d44a8","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/a56afb6aaef44d81bc49cf66a20d44a8","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Pharmacology Research & Perspectives, Vol 8, Iss 2, Pp n/a-n/a (2020)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.1002/prp2.567","doi":"https://doi.org/10.1002/prp2.567","is_oa":true,"landing_page_url":"https://doi.org/10.1002/prp2.567","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/prp2.567","source":{"id":"https://openalex.org/S2764487716","display_name":"Pharmacology Research & Perspectives","issn_l":"2052-1707","issn":["2052-1707"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmacology Research & Perspectives","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.98580002784729,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W3012537592.pdf","grobid_xml":"https://content.openalex.org/works/W3012537592.grobid-xml"},"referenced_works_count":30,"referenced_works":["https://openalex.org/W2001650386","https://openalex.org/W2013190669","https://openalex.org/W2111354448","https://openalex.org/W2148445312","https://openalex.org/W2169170125","https://openalex.org/W2473505427","https://openalex.org/W2492928450","https://openalex.org/W2550207834","https://openalex.org/W2594986299","https://openalex.org/W2623864543","https://openalex.org/W2718582600","https://openalex.org/W2728093281","https://openalex.org/W2736411845","https://openalex.org/W2737197277","https://openalex.org/W2757941745","https://openalex.org/W2766819558","https://openalex.org/W2770965214","https://openalex.org/W2787266772","https://openalex.org/W2792811290","https://openalex.org/W2795835597","https://openalex.org/W2800794691","https://openalex.org/W2803715733","https://openalex.org/W2805181790","https://openalex.org/W2895868360","https://openalex.org/W2898072840","https://openalex.org/W2901687990","https://openalex.org/W2931739625","https://openalex.org/W2955283194","https://openalex.org/W3007053288","https://openalex.org/W3013502865"],"related_works":["https://openalex.org/W4389449071","https://openalex.org/W4312761054","https://openalex.org/W3205555899","https://openalex.org/W4410898542","https://openalex.org/W3134813359","https://openalex.org/W4388222991","https://openalex.org/W4402010134","https://openalex.org/W7139031905","https://openalex.org/W4389442210","https://openalex.org/W4292590104"],"abstract_inverted_index":{"Abstract":[0],"Eptinezumab":[1],"is":[2,12,27],"a":[3,126,174],"humanized":[4],"mAb":[5],"that":[6,135],"targets":[7],"calcitonin":[8],"gene\u2010related":[9],"peptide":[10],"and":[11,21,48,99,125,146,153,173,180,197],"under":[13],"regulatory":[14],"review":[15],"for":[16,226],"the":[17,57,93,187,201,209,249],"prevention":[18],"of":[19,38,109,116,122,129,176,208,216,253],"episodic":[20],"chronic":[22],"migraine":[23,104],"(EM,":[24],"CM).":[25],"It":[26],"important":[28],"to":[29,68,76,149,205],"determine":[30],"whether":[31],"exposures":[32,230],"achieved":[33],"with":[34,62,86,158,165,169,223,232],"intravenous":[35],"(IV)":[36],"administration":[37],"eptinezumab":[39,58,96,110,195,217],"achieve":[40,206],"desired":[41],"pharmacologic":[42],"effects.":[43,240],"Population":[44],"pharmacokinetics,":[45],"including":[46,102,229],"dose\u2010":[47],"exposure\u2010response":[49,154],"analyses,":[50],"were":[51,147],"performed":[52],"using":[53],"patient\u2010level":[54],"data":[55],"from":[56,66],"clinical":[59,82],"trial":[60],"program":[61],"IV":[63,123],"doses":[64,160,170,236],"ranging":[65],"10":[67,75],"1000":[69],"mg":[70,78,162,172,199,247],"in":[71,79,84],"pharmacokinetic":[72,107,144,214],"analyses":[73,155],"or":[74,88,234],"300":[77,181,198],"phase":[80],"2/3":[81],"studies":[83],"patients":[85],"EM":[87],"CM.":[89],"Exposure\u2010response":[90],"analysis":[91,133,215],"explored":[92],"relationship":[94],"between":[95,178],"exposure":[97,157,188,202],"metrics":[98],"efficacy":[100,167,211,239,243],"parameters":[101,145],"monthly":[103],"days.":[105,131],"The":[106,241],"profile":[108],"was":[111,163],"characterized":[112],"by":[113,193],"rapid":[114],"attainment":[115],"maximum":[117],"plasma":[118],"concentration":[119],"(ie,":[120],"end":[121],"administration)":[124],"terminal":[127],"half\u2010life":[128],"27":[130],"Covariate":[132],"found":[134,156,186],"patient":[136,227],"characteristics":[137],"had":[138],"no":[139,224],"clinically":[140],"significant":[141],"effects":[142],"on":[143],"insufficient":[148],"influence":[150],"dosing.":[151],"Dose\u2010":[152],"single":[159],"\u2265100":[161],"associated":[164,231],"greater":[166],"compared":[168],"\u226430":[171],"plateau":[175],"effect":[177],"100":[179,196,246],"mg.":[182],"A":[183],"saturable":[184],"inhibitoryEmaxmodel":[185],"over":[189],"12":[190,221],"weeks":[191,222],"produced":[192],"single\u2010dose":[194],"exceeded":[200],"estimates":[203],"required":[204],"90%":[207],"maximal":[210],"(EC90).":[212],"This":[213],"supports":[218],"dosing":[219],"every":[220],"adjustment":[225],"characteristics,":[228],"100\u2010":[233],"300\u2010mg":[235],"producing":[237],"optimal":[238],"similar":[242],"profiles":[244],"support":[245],"as":[248],"lowest":[250],"effective":[251],"dose":[252],"eptinezumab.":[254]},"counts_by_year":[{"year":2026,"cited_by_count":5},{"year":2025,"cited_by_count":13},{"year":2024,"cited_by_count":8},{"year":2023,"cited_by_count":7},{"year":2022,"cited_by_count":16},{"year":2021,"cited_by_count":11},{"year":2020,"cited_by_count":6}],"updated_date":"2026-11-03T10:50:19.383937","created_date":"2020-03-23T00:00:00"}